PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34435474-8	2021	CONCLUSION: Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs.	Alitretinoin	81-93	TSPY like 2	Homo sapiens	54-58	
34435474-8	2021	CONCLUSION: Considering that nearly two thirds of the CTCL patients treated with alitretinoin showed a response or stable disease, together with a low number of side effects and low cost compared to bexarotene, alitretinoin may be a potential alternative in the treatment of less advanced CTCLs.	Alitretinoin	211-223	TSPY like 2	Homo sapiens	54-58	
33429396-3	2021	This study evaluated the efficacy and tolerability of alitretinoin in CTCL management.	Alitretinoin	54-66	TSPY like 2	Homo sapiens	70-74	
33429396-4	2021	METHODS: A retrospective, multicenter study was conducted on CTCL patients treated with alitretinoin as a primary agent or in combination with standard therapies.	Alitretinoin	88-100	TSPY like 2	Homo sapiens	61-65	
33429396-9	2021	Both early and advanced stages of CTCL were responsive to alitretinoin as a primary or combined modality.	Alitretinoin	58-70	TSPY like 2	Homo sapiens	34-38	
33429396-12	2021	CONCLUSIONS: This retrospective analysis supports the efficacy and safety of alitretinoin in clearing skin disease and preventing disease progression in CTCL as a monotherapy or in combination with standard therapies.	Alitretinoin	77-89	TSPY like 2	Homo sapiens	153-157	
30198914-1	2019	The vitamin A derivative 9-cis-retinoic acid (9-cis-RA) has been used for the treatment and prevention of cutaneous T-cell lymphoma (CTCL).	Alitretinoin	25-44	TSPY like 2	Homo sapiens	133-137	
30198914-1	2019	The vitamin A derivative 9-cis-retinoic acid (9-cis-RA) has been used for the treatment and prevention of cutaneous T-cell lymphoma (CTCL).	Alitretinoin	46-54	TSPY like 2	Homo sapiens	133-137	
30198914-2	2019	However, the precise mechanism by which 9-cis-RA treatment ameliorates CTCL remains elusive.	Alitretinoin	40-48	TSPY like 2	Homo sapiens	71-75	
30198914-3	2019	Our research shows that 9-cis-RA inhibits proliferation and induces apoptosis in CTCL cells in a dose-dependent and time-dependent manner.	Alitretinoin	24-32	TSPY like 2	Homo sapiens	81-85	
30198914-7	2019	Thus, 9-cis-RA may be effective for chemotherapy and may prevent human CTCL by inhibiting proliferation and inducing apoptosis by inhibition of the JAK/STAT pathway and activation of the RAR/RXR pathway.	Alitretinoin	6-14	TSPY like 2	Homo sapiens	71-75	
25175592-13	2015	CONCLUSION: In our group of CTCL patients we noticed a low rate of side-effects and an overall good clinical response to treatment with alitretinoin.	Alitretinoin	136-148	TSPY like 2	Homo sapiens	28-32